Amylyx Pharmaceuticals Stock Rises on Pipeline Progress

Amylyx Pharmaceuticals (AMLX) saw its stock rise due to progress in its drug pipeline, particularly with the peer-reviewed publication of Phase 2 trial data for AMX0035. The company also reported Q1 2026 results and ongoing developments that are influencing investor sentiment.

By May 22 at 7:55 AM | marketbeat.com · Auto-Fetched Original Sources · May 25, 2026, 21:26 UTC

Tickers: $AMLX

Topics: Pharmaceuticals Pipeline Development Q1 Results

Read the full article at Auto-Fetched Original Sources

More World news

Canadian Tire Announces Quarterly Dividend of CAD 1.825 Per Share Seeking Alpha · November 12, 2026, 13:58 UTC
Chicago Atlantic BDC Announces $0.34 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 13:59 UTC
William Blair Upgrades AMD to Outperform Amid Leadership Crisis at Nvidia CNBC · November 12, 2026, 13:56 UTC
HawkEye 360 Secures $135 Million in New Global Contracts Seeking Alpha · November 12, 2026, 13:55 UTC
Databento Secures $100 Million Series C Funding at $1.1 Billion Valuation PR Newswire · November 12, 2026, 13:57 UTC
Annex Brands Announces Franchise Renewal for Postal Connections in Fort Mohave, Arizona PR Newswire · November 12, 2026, 13:58 UTC
Nvidia CEO Jensen Huang Resigns Following Personal Scandals and Espionage Allegations The Verge · November 12, 2026, 13:53 UTC
AMD and PsiQuantum Partner to Develop Fault-Tolerant Quantum Computing Infrastructure Seeking Alpha · November 12, 2026, 13:44 UTC
Nvidia CEO Jensen Huang Resigns; CFO Colette Kress Appointed Interim CEO Seeking Alpha · November 12, 2026, 13:50 UTC
Aktis Oncology Reports Q3 Revenue Growth and Significant Increase in Cash Reserves Seeking Alpha · November 12, 2026, 13:50 UTC